Found: 7
Select item for more details and to access through your institution.
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 201, n. 1, p. 43, doi. 10.1007/s10549-023-06998-w
- By:
- Publication type:
- Article
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 200, n. 3, p. 43, doi. 10.1007/s10549-023-06998-w
- By:
- Publication type:
- Article
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 199, n. 1, p. 13, doi. 10.1007/s10549-023-06895-2
- By:
- Publication type:
- Article
Molecular mechanism of PdxR - a transcriptional activator involved in the regulation of vitamin B<sub>6</sub> biosynthesis in the probiotic bacterium Bacillus clausii.
- Published in:
- FEBS Journal, 2015, v. 282, n. 15, p. 2966, doi. 10.1111/febs.13338
- By:
- Publication type:
- Article
How pyridoxal 5′-phosphate differentially regulates human cytosolic and mitochondrial serine hydroxymethyltransferase oligomeric state.
- Published in:
- FEBS Journal, 2015, v. 282, n. 7, p. 1225, doi. 10.1111/febs.13211
- By:
- Publication type:
- Article
Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 11, p. 1626, doi. 10.1002/psp4.12910
- By:
- Publication type:
- Article
Screening and In Vitro Testing of Antifolate Inhibitors of Human Cytosolic Serine Hydroxymethyltransferase.
- Published in:
- ChemMedChem, 2015, v. 10, n. 3, p. 490, doi. 10.1002/cmdc.201500028
- By:
- Publication type:
- Article